State of Wyoming Purchases 53,397 Shares of Sotera Health Company $SHC

State of Wyoming lifted its position in shares of Sotera Health Company (NASDAQ:SHC) by 420.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,092 shares of the company’s stock after acquiring an additional 53,397 shares during the period. State of Wyoming’s holdings in Sotera Health were worth $735,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vident Advisory LLC boosted its stake in Sotera Health by 23.9% during the 2nd quarter. Vident Advisory LLC now owns 17,419 shares of the company’s stock valued at $194,000 after purchasing an additional 3,364 shares during the last quarter. Tidal Investments LLC bought a new position in shares of Sotera Health during the second quarter valued at $199,000. Sculptor Capital LP boosted its position in shares of Sotera Health by 27.2% during the second quarter. Sculptor Capital LP now owns 11,500,000 shares of the company’s stock valued at $127,880,000 after buying an additional 2,462,489 shares during the last quarter. Onex Canada Asset Management Inc. increased its holdings in Sotera Health by 61.6% in the 2nd quarter. Onex Canada Asset Management Inc. now owns 414,095 shares of the company’s stock worth $4,605,000 after buying an additional 157,826 shares in the last quarter. Finally, Lazard Asset Management LLC increased its holdings in Sotera Health by 230.6% in the 2nd quarter. Lazard Asset Management LLC now owns 34,974 shares of the company’s stock worth $388,000 after buying an additional 24,395 shares in the last quarter. 91.03% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on SHC. BMO Capital Markets began coverage on shares of Sotera Health in a research note on Thursday, November 13th. They set an “outperform” rating and a $19.00 target price on the stock. Piper Sandler increased their price objective on shares of Sotera Health from $15.00 to $17.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. raised their target price on shares of Sotera Health from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Sotera Health in a research note on Monday, December 8th. Finally, Barclays raised their price target on Sotera Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.80.

Insiders Place Their Bets

In other news, Director Gtcr Investment Xi Llc sold 6,480,000 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $16.33, for a total value of $105,818,400.00. Following the transaction, the director owned 22,735,301 shares of the company’s stock, valued at $371,267,465.33. This trade represents a 22.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Pincus & Co. Warburg sold 9,720,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $16.33, for a total value of $158,727,600.00. Following the transaction, the director owned 34,102,952 shares of the company’s stock, valued at approximately $556,901,206.16. This trade represents a 22.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 29,384,104 shares of company stock worth $471,824,511 over the last quarter. 55.12% of the stock is currently owned by corporate insiders.

Sotera Health Stock Performance

Shares of NASDAQ SHC opened at $16.83 on Monday. The company has a current ratio of 2.38, a quick ratio of 2.18 and a debt-to-equity ratio of 4.04. Sotera Health Company has a 12-month low of $9.53 and a 12-month high of $17.78. The firm has a market capitalization of $4.78 billion, a price-to-earnings ratio of 88.58 and a beta of 1.81. The firm has a 50 day moving average of $16.40 and a 200 day moving average of $14.53.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.04. The business had revenue of $311.31 million for the quarter, compared to analysts’ expectations of $303.63 million. Sotera Health had a net margin of 4.82% and a return on equity of 43.69%. Sotera Health has set its FY 2025 guidance at 0.810-0.860 EPS. On average, research analysts anticipate that Sotera Health Company will post 0.61 earnings per share for the current year.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.